ID
37273
Description
Study ID: 104864/902 Clinical Study ID: 104864/902 Study Title: An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00316173 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: CARBOPLATIN Study Indication: Ovarian Cancer; Neoplasms, Ovarian
Keywords
Versions (1)
- 7/12/19 7/12/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 12, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
HYCAMTIN in Combination With Carboplatin in Subjects with Ovarian Cancer; NCT00316173
Investigational Product Discontinuation
- StudyEvent: ODM
Description
Investigational Product Discontinuation
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0457454
Description
Experimental drug, Discontinued, Reason and justification
Data type
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1444662
- UMLS CUI [1,3]
- C0566251
Description
Experimental drug, Discontinued, Reason and justification
Data type
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1444662
- UMLS CUI [1,3]
- C0566251
Similar models
Investigational Product Discontinuation
- StudyEvent: ODM
C0457454 (UMLS CUI-2)
C1444662 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])
C1444662 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])